Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2022, with a specific reporting date of March 15, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Transaction Type |
|---|---|---|---|---|
| March 11, 2022 | Ordinary Shares (25p each) | £12.09 | 1,934 | Acquisition via ShareSave Plan |
Breakdown of Transactions:
- Ms. S. Jackson (SVP, Global Communications and CEO Office): Acquired 744 shares.
- Mr. D. Jackson (PCA of Ms. S. Jackson): Acquired 744 shares.
- Mr. P. Thomson (President, Global Affairs): Acquired 446 shares.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents routine equity compensation exercises.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed under the Company's ShareSave Plan involving options granted on November 29, 2018, and were conducted on the London Stock Exchange (XLON).
Investor Verification Checklist
- Verify the total number of shares acquired by insiders (1,934) against the company's broader insider trading reports for the quarter.
- Confirm the exercise price (£12.09) aligns with the grant date of November 29, 2018, and current market conditions.
- Check subsequent filings to determine if these shares were held or sold shortly after acquisition.
- Note that this filing provides no data on GSK's operational performance or financial health for the period.